{
    "clinical_study": {
        "@rank": "166542", 
        "acronym": "SUDIA", 
        "arm_group": [
            {
                "arm_group_label": "Single rocuronium dose - placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The patients will receive a single rocuronium dose, and no reversal agent."
            }, 
            {
                "arm_group_label": "Single rocuronium dose - sugammadex", 
                "arm_group_type": "Active Comparator", 
                "description": "The patients will receive a single rocuronium dose and sugammadex 2mg/kg as a reversal agent"
            }, 
            {
                "arm_group_label": "Repeated rocuronium dose - neostigmine", 
                "arm_group_type": "Active Comparator", 
                "description": "The patients will receive multiple rocuronium doses and neostigmine 70 mcg/kg as a reversal agent"
            }, 
            {
                "arm_group_label": "Repeated rocuronium dose - sugammadex", 
                "arm_group_type": "Active Comparator", 
                "description": "The patients will receive multiple rocuronium doses and neostigmine 2mg/kg as a reversal agent"
            }, 
            {
                "arm_group_label": "Continuous rocuronium dose", 
                "arm_group_type": "Active Comparator", 
                "description": "The participants will receive a continuous rocuronium infusion and sugammadex 4 mg/kg as a reversal agent"
            }
        ], 
        "brief_summary": {
            "textblock": "The effect of neuromuscular blocking agents (NMBA, e.g. rocuronium) on respiratory muscle\n      activity is well known. However, since the availability of sugammadex, to our knowledge, no\n      study has been conducted to evaluate the effect of this novel product on these muscles.\n\n      Our hypothesis is that by applying a different strategy in the use of neuromuscular blocking\n      agents and their reversal agents we might see a different activity of the respiratory\n      muscles."
        }, 
        "brief_title": "Recovery of Diaphragmatic Function After Neuromuscular Blockade and Sugammadex", 
        "condition": [
            "Diaphragmatic Dysfunction", 
            "Muscle Weakness", 
            "Muscle Fatigue"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Asthenia", 
                "Fatigue", 
                "Muscle Weakness", 
                "Paresis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Each participant must have the mental capacity to decide whether he/she takes part in\n             the trial or not. Each participant must voluntarily give his/her written informed\n             consent. In case a participant is physically unable to give a written informed\n             consent, a legal representative is to perform this.\n\n          -  Each participant must be at least eighteen years of age. Participants can be of\n             either sex and of any ethnical background.\n\n          -  Each participant must meet the American Society of Anesthesiologists class II, II or\n             III criteria.\n\n          -  Each participant must be scheduled for intracranial surgery. During general\n             anesthesia rocuronium must be used as a neuromuscular blocking agent.\n\n          -  Each participant must be a suitable candidate for the rapid reversal of the\n             neuromuscular blockade.\n\n          -  Each female participant of sexually active age and of childbearing potential must\n             agree to the use of a medically accepted method of contraception through seven days\n             after the day of surgery. Postmenopausal (defined as at least twelve consecutive\n             months without spontaneous menstrual period) women are not obliged to use\n             contraceptives.\n\n        Exclusion Criteria:\n\n          -  The participant is known or suspected to have a neuromuscular disorder.\n\n          -  The participant is known or suspected to have an allergic reaction to sugammadex,\n             rocuronium, anesthetic or narcotic medications, or any drugs used during general\n             anesthesia.\n\n          -  The participant is known or suspected to have an anatomical malformation impeding a\n             proper intubation.\n\n          -  The participant is known or suspected to have a history of malignant hyperthermia.\n\n          -  The participant is pregnant (or intends to become pregnant within the presurgical\n             period) or lactating.\n\n          -  The participant is known to have a renal insufficiency (defined as a serum creatinine\n             concentration of two times the upper limit, or a glomerular filtration rate of less\n             than 60 ml/min).\n\n          -  The participant is known or suspected to have a chronic obstructive pulmonary disease\n             GOLD classification 2 or higher or has any respiratory disease that impairs his\n             respiratory function to a NYHA III level or worse.\n\n          -  The participant is known to have an infection of the upper or lower airways, as\n             diagnosed by clinical or laboratory findings.\n\n          -  The participant is known or suspected to have congestive heart failure.\n\n          -  The participant is obese, as defined by a body mass index of 30 kg/m2 or more.\n\n          -  The participant is known or suspected to have a major hepatic dysfunction.\n\n          -  The participant has received or is scheduled to receive toremifene and/or an\n             intravenous administration of fusidic acid within a time span of twenty-four hours\n             before and twenty-four hours after the surgery.\n\n          -  The participant is known or suspected to have any condition contraindicating the\n             administration of sugammadex, neostigmine, glycopyrrolate or placebo.\n\n          -  The participant is known or suspected to be directly involved in this study and/or is\n             employed by or is a family member of any person employed by the investigator, at the\n             investigational site, or by the sponsor."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01962298", 
            "org_study_id": "EC 13/5/60", 
            "secondary_id": [
                "2013-001926-25", 
                "B300201316844"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Single rocuronium dose - sugammadex", 
                    "Repeated rocuronium dose - sugammadex"
                ], 
                "intervention_name": "sugammadex 2mg/kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Repeated rocuronium dose - neostigmine", 
                "intervention_name": "neostigmine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Continuous rocuronium dose", 
                "intervention_name": "sugammadex 4mg/kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Single rocuronium dose - placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Single rocuronium dose - placebo", 
                    "Single rocuronium dose - sugammadex"
                ], 
                "intervention_name": "Single rocuronium dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Repeated rocuronium dose - neostigmine", 
                    "Repeated rocuronium dose - sugammadex"
                ], 
                "intervention_name": "Repeated rocuronium dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Continuous rocuronium dose", 
                "intervention_name": "Continuous rocuronium infusion", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Neostigmine", 
                "Rocuronium"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 11, 2013", 
        "location": {
            "contact": {
                "email": "tom.schepens@uza.be", 
                "last_name": "Tom Schepens, MD", 
                "phone": "00323821", 
                "phone_ext": "3265"
            }, 
            "facility": {
                "address": {
                    "city": "Edegem", 
                    "country": "Belgium", 
                    "state": "Antwerpen", 
                    "zip": "2650"
                }, 
                "name": "Antwerp University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Tom Schepens, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Marcel PE Vercauteren, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Vera Saldien, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "5", 
        "official_title": "Sugammadex and the Diaphragm: Recovery of Diaphragmatic Function and Neuromuscular Blockade. A Double-blind Randomized Controlled Trial", 
        "other_outcome": {
            "measure": "Centroid frequency of the EMG, as trend variability (change in %) from first to last recording", 
            "safety_issue": "No", 
            "time_frame": "From the start of spontaneous breathing till extubation, limited to maximum one hour after the onset of spontaneous breathing"
        }, 
        "overall_contact": {
            "email": "tom.schepens@uza.be", 
            "last_name": "Tom Schepens, MD", 
            "phone": "00323821", 
            "phone_ext": "3265"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Electric activity of the diaphragm (microvolts) and tidal volume (milliliter) in a breath-by-breath analysis", 
            "safety_issue": "No", 
            "time_frame": "From the start of spontaneous breathing till extubation, limited to maximum one hour after the onset of spontaneous breathing"
        }, 
        "reference": {
            "PMID": "23011532", 
            "citation": "Dres M, Schmidt M, Ferre A, Mayaux J, Similowski T, Demoule A. Diaphragm electromyographic activity as a predictor of weaning failure. Intensive Care Med. 2012 Dec;38(12):2017-25. doi: 10.1007/s00134-012-2700-3. Epub 2012 Sep 26."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01962298"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital, Antwerp", 
            "investigator_full_name": "Tom Schepens, MD", 
            "investigator_title": "Tom Schepens, MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Number of events with oxygen saturation below 90% measured by pulse oximetry", 
            "safety_issue": "Yes", 
            "time_frame": "The first hour post-extubation"
        }, 
        "source": "University Hospital, Antwerp", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Antwerp", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}